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Abstract 
 
Utilization of donation after circulatory death donor (DCD) livers for transplantation has 
remained cautious in the U.S. The aim of this study was to demonstrate the expansion of DCD liver 
transplant (LT) program with the use of extended criteria DCD livers. After institutional review board 
approval, 135 consecutive DCD LTs were retrospectively studied. ECD DCD livers were defined as 
those with one of the followings: 1) donor age >50 years, 2) donor BMI >35 kg/m
2
, 3) donor 
functional warm ischemia time (fWIT) >30 minutes, and 4) donor liver macrosteatosis >30%. An 
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optimization protocol was introduced in July 2011 to improve outcomes of DCD LT, which included 
thrombolytic donor flush, and efforts to minimize ischemic times. The impact of this protocol on 
outcomes was evaluated in terms of graft loss, ischemic cholangiopathy (IC) and change in DCD LT 
volume. Of 135 consecutive DCD LT, 62 were ECD DCDs. 24 ECD DCD LT were performed before 
(Era I) and 38 after the institution of optimization protocol (Era II), accounting for an increase in the 
use of ECD DCD livers from 39% to 52%. Overall outcomes of ECD DCD LT improved in Era II, 
with a significantly lower incidence of IC (5% vs. 17% in Era I; P = 0.03) and better 1-year graft 
survival (93% vs. 75% in Era I, P = 0.07). Survival outcomes for ECD DCD LT in Era II were 
comparable to matched deceased donor (DBD) LT. With the expansion of the DCD donor pool, the 
number of DCD LT performed at our center gradually increased in Era II to account for > 20% of the 
center’s LT volume. In conclusion, with the optimization of perioperative conditions, ECD DCD 
livers can be successfully transplanted to expand the donor pool for LT.   
 
Introduction 
Donation after circulatory death (DCD) donors have expanded the donor pool, however 
utilization of these livers remain cautious in the U.S. [1] The number of DCD donors has doubled in 
the last decade (642, 8% of 8017 total donors in 2006 vs. 1684,17% of 9971 total donors in 2016); 
only 27% (518/1884) of the DCD livers were transplanted in 2017. [1] The reluctance to transplant 
DCD livers stems from several initial studies that published worse outcomes, mainly attributing to 
ischemic cholangiopathy (IC). [2-5] Due to initial worse outcomes with DCD LT, the American 
Society of Transplant Surgeons (ASTS) recommended practice guidelines for DCD procurement and 
transplantation in 2009 which emphasized limiting the use of DCD donor livers with (i) longer 
ischemia times or (ii) from older donors. [2-4] Variables, such as older donor age, prolonged cold 
ischemia time (CIT) and donor warm ischemia time (WIT) have been identified as the important risk 
factors associated with worse outcome, particularly for IC. [2-6] However, application of these 
criteria has led to underutilization of extended criteria donor (ECD) DCD livers. [1] A clear trend of 
transplanting DCD livers from younger donors was seen nationally, and only 13% DCD LTs were 
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from donors >50 years old between 2005 and 2015. [OPTN.org] 
Recently, The Mayo group has shown comparable outcomes of DCD LT using donors >50 
years age to that with younger donors as well as deceased donor LT. [7] Our and other programs have 
also reported improved results after DCD LT with outcomes comparable to deceased donor LT [8, 9] 
[10]. Improved outcomes were attributed to donor selection, minimization of CIT, and the use of 
thrombolytics. [11, 12] [13]Although these are important achievements, a large number of ECD DCD 
livers still remain underutilized in the U.S., compared to  European centers. [10, 14] Schlegel et al, 
from Birmingham U.K., have demonstrated DCD livers from donors >60 years age can be 
successfully used with good long-term outcomes when other risk factors are limited. [14] The Zurich 
experience with hypothermic oxygenated perfusion (HOPE) has shown good 5-year outcomes despite 
extended donor warm ischemia and median donor age 57 years and median fWIT 31 minutes. [15]  
In this study, we present our experience with the use of ECD DCD livers with comparable 
outcomes to matched deceased donor (DBD) LTs.   
Methods 
Study population 
Patients with at least 6 months follow up were included in the study. The retrospective 
analysis of data between 08/2003- 05/2018 from the transplant research database at our center was 
reviewed and approved by the institutional review board of the Indiana University School of 
Medicine. Outcomes of adult DCD LTs (n=135) were evaluated. Due to the introduction of DCD LT 
optimization protocol in 07/2011, two eras were defined for the DCD LT. Patients with less than 12 
months follow up were excluded from the survival analysis. For comparison of ECD DCD LTs with 
DBD LTs, a case-control matched analysis on propensity score was performed to reduce selection 
bias. The propensity score was estimated with the use of a multivariable logistic regression model. 
Matching was performed with the use of a 1:2 matching protocol without replacements. DBD LTs 
were matched with ECD DCD LTs with respect to the year of transplant, recipient age, gender, 
MELD score, CIT, recipient WIT, donor age, and donor gender. 
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Definitions  
ECD DCD livers were defined as those with one or more of the following factors: 1) donor 
age >50 years, 2) donor BMI >35 kg/m
2
, 3) donor fWIT >30 minutes, and 4) donor liver 
macrosteatosis >30%. The definition of ECD DCD livers was based on the current national DCD liver 
acceptance practices, ASTS recommendations [10], and single-center experiences reported in the 
literature. [2-9, 11-15, 19]. Era I DCD LT included those performed between 08/2003-06/2011 
(n=62). Era II DCD LT included those performed with the ‘DCD LT Optimization Protocol’ from 
07/2011onwards with at least 6 months follow up (n=73).  Donor total WIT (tWIT) was defined as the 
time from extubation to in-situ perfusion. The time period from donor mean arterial pressure less than 
50 mmHg and/or oxygen saturation less than 70% to in-situ perfusion was considered as functional 
WIT (fWIT). CIT was defined as the time from cold perfusion to portal reperfusion. Similar to 
Kroome et al, [7] IC was defined as the presence of intrahepatic biliary strictures in the absence of 
hepatic artery thrombosis, which was confirmed either by endoscopic retrograde 
cholangiopancreatography, or magnetic resonance cholangiopancreatography, or percutaneous 
transhepatic cholangiography. [16, 17] Early allograft dysfunction (EAD) was defined, as described 
by Olthoff et al. [18]  
 
Organ procurement 
The technique of DCD liver procurement was previously described. [9] Briefly, 300 IU/ kg 
heparin was administered systemically at the time of withdrawal of life support. Procurement began 5 
minutes after the declaration of circulatory death. Immediately after entering the abdomen, distal aorta 
was cannulated and flushed with preservation solution and the infrarenal inferior vena cava vented for 
rapid exsanguination. Thoracic aorta was then clamped and the inferior vena cava was divided in the 
thoracic cavity. Ice-slush was placed on the abdominal organs and 3-4 liters of cold preservation 
solution was flushed through the aorta. Liver grafts were rapidly removed and an additional 500 mL 
of preservation solution was flushed through the portal vein on the back table. The common bile duct 
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was irrigated with cold preservation solution on the back table. Liver biopsies during procurement 
were performed based on procuring surgeons discretion to evaluate steatosis or necrosis. Post-
reperfusion liver biopsies were however performed in all cases. In the majority (6/7) of the cases, 
livers with macrosteatosis >30% were identified at the time of procurement.  
 
DCD LT Optimization Protocol (July 2011 to current; Era II) 
The optimization protocol comprised of two main components: 1) minimization of modifiable 
ischemic times (CIT, recipient WIT) and 2) thrombolytic donor flush. The details of the protocol were 
previously described. [9]  Briefly, during DCD procurements 100 mg of tissue plasminogen activator 
(tPA) (Activase®, Genetech Inc., CA, USA) was mixed in 1 liter of normal saline at room 
temperature, and was flushed through the aortic cannula as the initial flush after aortic clamping. This 
was followed by a 1 minute dwell period, followed by a 3-4 liters cold preservative fluid flush. After 
recovery of the liver, an additional 100 ml of tPA solution was injected into the celiac artery and the 
branches of celiac trunk were clipped until the back table preparation to avoid spillage. To minimize 
CIT, when possible, patients with a complex surgical history, extensive portal venous thrombosis 
were avoided as recipients. In order to make a quick decision regarding the usability of the organ at 
donor site In Era II, all procurements, including nationally shared livers were procured by our team 
which was led by surgeons experienced in DCD procurements. At our center, all procurements are led 
by attending surgeons. Two surgeons (P.M. & C.K.) who had developed particular expertise using the 
optimization protocol performed majority (90%) of the DCD procurements in Era II. As soon as the 
liver was considered transplantable, the recipient preparation for surgery was expedited. Recipient 
operation and back table preparation of the liver began simultaneously. Similarly, until 2017, all 
recipient operations were performed by staff surgeons to keep, hepatectomy time and recipient WIT 
short. 
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Recipient operation  
Recipient operation was previously described elsewhere. [19]  Briefly, the transplant 
operation was performed using a piggyback technique for the venous outflow. Hepatic artery was 
dissected and prepared for anastomosis during hepatectomy to avoid prolonged warm ischemia to the 
biliary system after portal reperfusion. Hepatic artery anastomosis was performed after reperfusion of 
the portal vein.  
 
Recipient selection 
At the beginning of Era II, recipient selection was cautious; recipients with portal vein 
thrombosis, prior upper abdominal surgeries (except cholecystectomy) were considered to be 
unsuitable initially. Also, the possibility of re-transplantation was also kept in mind while selecting 
recipients in the beginning. However, with initial success and growing experience, DCD allografts 
were offered to patients with surgical complexities and frailty in the latter half of Era II, although 
keeping ischemic times short.  
Clinical endpoints 
The clinical endpoints of our study were (i) graft loss, (ii) development of IC and (iii) 
expansion of the DCD donor pool with the use of ECD DCD donors. 
Statistical analysis 
Standard statistical testing was conducted with commercially available software (IBM SPSS, 
Version 24.0. Armonk, NY).  The comparisons were performed with the Mann-Whitney U-test for 
numerical data and the Chi-square test for categorical data. Survival rates were estimated with the 
Kaplan-Meier analysis. For comparison of ECD DCD LTs with DBD LTs, a 1:2 case-control 
propensity scores matched cohort of DBD LTs was used. All graft survival curves were calculated as 
non-death censored. A P value of <0.05 was considered statistically significant.  
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Results 
In Era I (8-year span) 62 (46%) DCD LTs were performed, whereas in Era II (~7 -year span) 
there were 73 (54%) DCD LTs.  Of 135 DCD LT, 62 were ECD DCD; 24 (39%) in Era I and 38 
(52%) in Era II.  
Donor, recipient and transplant characteristics 
Donor, transplant and recipient characteristics were compared between standard criteria donor 
(SCD) and ECD DCD LTs, separately for the two eras. (Table 1) As expected, donor age was higher 
in ECD DCDs in both eras, however median donor BMI was higher in ECD DCDs from Era I only. 
Overall, majority of ECD DCD livers were from regional (31%)  or national (29%) share compared to 
SCD DCD livers (23% & 12% respectively, chi-square, P = 0.01). However, in Era II, 62% of all 
DCD livers and 47% of ECD DCD livers were local (P = 0.01). In Era I, 18% DCD donor livers were 
flushed with University of Wisconsin (UW) solution, whereas Histidine-tryptophan-ketoglutarate 
(HTK) was exclusive preservation fluid used in Era II (100% vs. 82%, P = 0.001). Recipient 
demographics were comparable between SCD and ECD DCD LTs in both eras. There was an overall 
improvement in ischemic times in Era II. The ischemic times except for CIT for ECD DCDs in Era I 
were significantly longer than SCD DCDs. Median functional donor WIT was significantly longer in 
ECD DCDs [32(14-78) vs. 15(7-30); P = 0.001]. Median recipient WIT (anastomoses time) for ECD 
DCDs was also significantly longer than SCD DCDs [21(18-38) vs. 27(21-38); P = 0.001].  
Donor, transplant and recipient characteristics for ECD DCD LTs across the two eras were 
also compared. (Table 1) These comparisons revealed, comparable donor demographics, but older 
recipients, higher MELD scores, more male recipients, and higher recipient BMI in era II.  
In terms of transplant characteristics, CIT, total donor WIT, recipient WIT and hepatectomy 
times were significantly shorter for ECD DCDs in Era II. For example, median total WIT (donor 
functional WIT + recipient WIT) was 39(28-72) in Era II, compared to 58(38-108) in Era I, P < 0.001. 
The exclusive use of HTK as preservation fluid in ECD DCDs in Era II was also significant.   
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Post-transplant outcomes 
Post-transplant clinical outcomes for ECD DCD LTs were compared across the two eras. 
(Table 2) In Era II, the total bilirubin on post-transplant days 14 and 30 were significantly lower and 
day 3 - INR was significantly higher (Table 2). EAD was overall common in ECD DCDs and was 
comparable across the two eras (P = 0.69). In Era II, the prevalence of biliary anastomotic strictures 
was significantly lower (21% vs. 54% in Era I; P = 0.01). There were two cases of IC in Era II (5% 
vs. 17% in Era I, P = 0.01). Hepatic artery thrombosis occurred in 1 patient in each Era which resulted 
in retransplantation of both cases. In Era II, the patient with late hepatic artery thrombosis also 
developed intrahepatic diffuse biliary strictures. This was not considered as IC, due to the hepatic 
artery compromise.   
The outcomes of ECD DCD LT in Era II were compared with propensity score matched DBD 
LT (N = 124) (Table 2). Peak post-transplant transaminases (AST and ALT) were significantly higher 
in ECD DCD LTs in Era II compared to matched DBD LTs. Post-transplant bilirubin levels (on days 
7, 14, 30) were comparable between ECD DCD LT in Era II and matched DBD LT (Table 2). The 
post-transplant day 3 INR and incidence of EAD were also significantly higher in the ECD DCD (Era 
II) cohort. IC, hepatic artery thrombosis, and re-transplantation rates were similar between Era II ECD 
DCD LTs and matched DBD LTs.  
 
Survival outcomes 
Overall graft survival for ECD DCD LTs improved in Era II, compared to Era I, however, this 
was not statistically significant by Log-Rank test (P = 0.26). (Fig. 1a) 1-year graft survival was 
numerically higher in Era II ECD DCD LTs when compared with Era I ECD DCD LTs (93% vs. 
75%; P = 0.07) (Table 2). Overall graft survival for ECD DCD LT (Era II) was comparable to 
matched DBD LT (Log Rank, P = 0.8) (Fig. 1b). Similar trends were recorded for patient survival 
(data not shown). 1-year patient survival for ECD DCD LTs was numerically higher than that of ECD 
DCD LT in Era I (97% vs. 83%; Log Rank; P = 0.09) and matched DBD LT (97% vs. 90%; P = 
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0.25). Three patients receiving ECD DCD LTs in Era II died with functioning grafts at the time of 
death from cardiomyopathy, pneumonia, and stroke. One patient was retransplanted for intrahepatic 
biliary strictures secondary to late hepatic artery thrombosis. 
 
Ischemic cholangiopathy (IC) in ECD DCD LT  
Two patients (5%) in Era II receiving ECD DCD LTs developed IC compared to 4 patients 
(25%) in Era I (P = 0.01) (Table 2). Of 4 patients developing IC in Era I, 3 lost their grafts due to this 
complication. Of whom, one patient was re-transplanted 4.5 months after transplantation. In 1 patient, 
there were predominant right and left main hepatic duct strictures and were managed with repeated 
biliary interventions. In Era II, both patients developing IC were managed with endoscopic 
interventions and have normal liver function.    
 
Expansion of the DCD LT program with the use of ECD DCD 
Due to poor outcomes, the number of DCD LT performed per year decreased in the latter half 
of Era I. After the introduction of DCD LT optimization protocol in 2011, the DCD LT program 
expanded. [Fig. 2] Especially for 3 years since 2015, the successful expansion was from ECD DCD 
livers. In 2016, 2017, and 2018 ECD DCD livers constituted 59%, 60% and 56% of our DCD LT 
activity respectively. In 2015, 2016, and 2017, 9%, 12%, and 11% of all adult LT were DCD LT, 
respectively. In 2018, 32 out of 143 of adults LTs were DCDs accounting for 22% volume.  Donor 
selection evolved over the period of Era II. At the beginning of Era II, most of the DCD donors were 
SCD DCDs, from 2011 to 2014 out of 13 DCD LTs only two were ECD DCDs. With the initial 
success of having no IC or graft loss, we started utilizing ECD DCDs. Initially, we started utilizing 
livers donor age and BMI as ECD variables and from 2015 onwards we expanded our ECD variables 
to fWIT >30 minutes and macrosteatosis >30% was the last ECD variable to be incorporated. (Figure 
2) 
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ECD DCD variables (Table 3) 
There were 62 (54%) ECD DCD LTs (24 in Era I and 38 in Era II). The most common ECD 
criterion was donor age, followed by fWIT, donor BMI and macrosteatosis in this order. In Era II, 
graft loss was not associated with ECD criteria, unlike in Era I. For instance, in Era II, 16% ECD 
DCD livers were with donor fWIT >30 minutes (32, 33, 33, 37, 40 & 41 minutes) and none of these 
grafts failed. The threshold for fWIT was raised in the latter half of Era II. In 3 transplants, fWIT >30 
minutes was combined with other ECD variables such as BMI, macrosteatosis, and age. In Era I, LTs 
with more than one ECD criteria were associated with 100% graft loss. In Era II, none of the 6 grafts 
2 ECD variables failed. Of 6 livers were with macrosteatosis >30% in Era II, 1 graft loss occurred as a 
result of patient death. Interestingly, none of the livers with macrosteatosis >30% were from donors 
with BMI >35 kg/m
2
. When ECD DCD variables (donor age >50 years, donor BMI >35 kg/m
2
, donor 
fWIT >30 minutes, and donor macrosteatosis >30%) were considered individually with respect to the 
development of IC, EAD, and graft loss, no associations were found.  
 
Discussion  
This study demonstrates the use of ECD DCD livers to expand DCD LT program. The overall 
improvement in outcomes consolidates our previous experience with a protocol that utilizes 
thrombolytic donor flush along with short ischemic times. [9] Although, it is possible that we are now 
more adept and experienced in performing DCD LT. Similar to our experience, recently other centers 
[8] [12] and SRTR data-based reports [20]  have demonstrated improved outcomes after DCD LT. 
The explanation for improved outcomes in our series remains speculative since multiple changes were 
instituted. In our opinion, the most important factor responsible for improved outcomes was shorter 
CIT. It should also be noted that in Era I ECD DCD LTs were associated with significantly longer 
warm ischemic times than for SCD DCD LTs. It is possible that a combination of ECD factors with 
longer warm ischemic times in Era I was responsible for poor outcomes. The role of thrombolytic 
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flush is also compelling. Improved outcomes have also been reported by others without the use of 
heparin or thrombolysis, questioning the theory of microthrombi within peribiliary capillaries. [21] 
On the other hand, several groups have demonstrated improved outcomes with the use of 
thrombolysis. [8, 9, 12, 13] We believe that efforts should be made to shorten CIT in DCD LT in 
order to improve outcomes and expand the donor pool. Other studies have reiterated this observation. 
[20] [22] Selck et al showed 31% increased risk of graft loss associated with nationally shared DCD 
livers due to increased CIT. [23]  Similar to our experience in Era II, Detry et al have described 
excellent outcomes (IC in 1/70 patients) with a median CIT of 3.9 hours [24].  
 
Expanding DCD donor pool 
Risk factors associated with poor outcomes in DCD LT are already defined, and some of 
these are modifiable. This principle was exploited in our and other DCD series. [8, 9, 24] The 
modifiable donor risk factors are: 1) location of withdrawal of life support, 2) asystole to cross-clamp 
time, 3) post-mortem use of heparin, 4) interventions such as use of thrombolytics in the donor or 
recipient, normothermic perfusion after procurement, use of ECMO after cardiac arrest. [8, 9, 13, 25-
29] Additional modifiable recipient risk factors can be 1) hepatectomy time, 2) recipient WIT, and 3) 
CIT. [30-32] On the other hand, donor age, donor BMI, donor WIT, donor liver quality in terms of 
steatosis, transaminases are unmodifiable factors. Our approach has been to gradually expand the 
acceptance criteria to include unmodifiable risk factors. We started with donor age and BMI, then 
gradually expanded to livers with >30 minutes fWIT and >30% macrosteatosis. There were 6 
transplants with donor fWIT >30, 32, 33, 33, 37, 40 & 41 minutes. We believe that donor fWIT can 
be safely extended up to 40 minutes in select cases, particularly with short CIT, and short recipient 
WIT. Another important observation in our study was that of 11 ECD DCD donors with BMI >35,  
none had macrosteatosis >30%, emphasizing that DCD liver should not be discarded based on BMI 
alone. Also, quantification of macrosteatosis on frozen section biopsies can be variable and is 
frequently overestimated on frozen sections. Although we do not use a cut-off value for % 
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macrosteatosis in our DCD liver program, we believe that DCD livers with little over >30% 
macrosteatosis on frozen sections can be used safely with relatively healthy-appearing remaining 
hepatocytes, with soft liver parenchyma and short ischemic times.  
Recipient selection remains important to successful outcomes. As our experience 
grew with DCD LT, we gradually relaxed our recipient selection criteria to include recipients 
with surgical complexities and portal vein thrombosis. Currently, the only recipient 
contraindication to DCD LT is the previous LT. We also keep in mind that recipients of ECD 
DCD grafts should have overall health to tolerate re-transplantation in the event of IC and 
graft loss.  
 
Definition of ECD DCD LT 
Currently, there are no established criteria for ECD DCD LT. In this study, we defined ECD 
DCD criteria based on organ acceptance practices in the U.S. to identify potentially transplantable 
livers and previous ASTS practice guidelines on DCD liver transplantation. [4] We chose donor age 
>50 years as one of the criteria because, from 2005-2015, only 13% DCD LTs were performed from 
donors older than 50 years nationally. Croome et al from UNOS data reported a decline in DCD LTs 
from donors >50 years age from 18% (2003-2006) to 11% in 2011-2014. [20] Although many 
European centers have reported the successful use of DCD livers from donors older than 60 years, 
[14] only 4% DCD donors pursued for organ procurements in the U.S. from 2005-2015 were >60 
years old. On the contrary 24%, DCD donors pursued during this period nationally were from 51-60 
years of age group, making this donor age group the first target to expand the donor pool. The second 
criterion in our definition was donor BMI >35. Median donor BMI for national DCD LTs from 2005-
2015 was 25.5 with 29.5 as the 75
th
 percentile. To stay beyond the upper limit of BMI margin for 
livers being currently transplanted, we chose a BMI of 35. Another huge potential to expand the DCD 
donor pool relates to the donor WIT. It is astonishing that only 5% of DCD LTs performed nationally 
between 2011-2014 were with total donor WIT >30 minutes. [20] It must be noted that this was total 
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donor WIT and not functional, hence it is likely that several of the discarded livers would have had 
<30 minutes functional WIT. The major disadvantage of using total donor WIT as an organ 
acceptance criterion is that it does not truly reflect the conditions inflicting liver injury from warm 
ischemia during the agonal phase. Therefore, to exclude the period with normal vital parameters, we 
used fWIT of  >30 minutes as our third criterion. Our fourth criterion was % macrosteatosis. We 
adopted a cut off level of 30% for the macrosteatosis based on the ECD definition for DBD livers. 
[33]  
 
Limitations 
This study has several limitations. We could not exclude the possibility of bias from 
unobserved variables due to the retrospective nature of the study. There were confounding factors 
such as increased experience with DCD LT & improved recipient selection. In this study, we used 
historic controls, as a randomized controlled study was not possible due to the risk involved. 
However, most published studies on DCD LT are retrospective single center and/or national database 
studies. 
 
Conclusions 
ECD DCD livers can be used successfully to expand donor liver pool. Outcomes comparable 
to DBD LT can be achieved despite the use of donors >50 years of age, donors with high BMI, and 
livers with relatively longer donor WIT, and macrosteatosis. With the recent success in this field, 
updated guidelines on DCD liver procurement and transplantation are required to expand DCD LT 
nationally. 
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Figure Legends: 
Figure 1a: Graft survival by Kaplan-Meier analysis for ECD DCD LTs stratified by two eras.   
Graft survival not censored for death for ECD DCD LTs compared across the two eras, Log Rank; P 
= 0.26.  
 
Figure 1b: Graft survival by Kaplan-Meier analysis for Era II ECD DCD LTs compared with 
matched DBD LTs.   
Graft survival not censored for death for ECD DCD LTs in Era II compared to graft survival for 
propensity score matched DBD LTsacross the two eras, Log Rank; P =0.8. Cases were matched for 
year of transplant, recipient age, gender, CIT, recipient WIT, donor age, and donor BMI.  
 
Figure 2: Number of all DCD LTs performed at Indiana University since 2003.  
Gray bar indicates standard criteria donor (SCD) donation after circulatory death (DCD) donor LT. 
The black bar indicates extended criteria donor (ECD) DCD LT. The numbers indicate percentages of 
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DCD LTs on overall adult LTs of each year performed at Indiana University. The DCD LT 
Optimization protocol was introduced in July 2011.  
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Table 1. Donor and recipient demographics data for DCD LT in Era I and Era II, stratified by ECD status.  
 
  
Era I 
SCD DCD 
n=38 
Era I 
ECD DCD  
n=24 
 
p-value 
 
Era II 
SCD DCD 
n=35 
Era II 
ECD DCD 
n=38 
 
p-value 
p-value 
Era I ECD DCD  
vs. Era II ECD DCD 
DONOR        
Age (years) 40 (12-50) 42 (21-58) <0.001 31 (9-53) 46 (12-62)  <0.001  0.37 
Gender: Male 28 (73) 13(54) 0.11 29 (79) 30 (83)  0.67  0.11 
Body mass index (kg/m
2
) 24 (14-32) 24 (20-40) 0.01 26 (14-32) 25 (19-48)  0.18  0.35 
 
Organ origin 
Local 
Regional share  
   National share 
 
 
20 (53) 
10 (26) 
8 (21) 
 
 
7 (29) 
7 (29) 
10 (42) 
  
 
27 (77) 
7 (20) 
1 (3) 
 
 
18 (47) 
12 (32) 
8 (21) 
 
 
 0.01 
 
 
 
 
 0.18 
 
 
Preservation fluid  
       
   HTK  33 (87) 18 (75) 0.23 38 (100) 38 (100) --  0.001 
   UW 5 (13) 6 (25)  0 (0) 0 (0)   
RECIPIENT        
Age (years) 54 (40-71) 53 (24-65) 0.08 57 (33-68) 61 (39-72)  0.25  <0.001 
MELD*  15 (9-24) 14 (8-27) 0.2 20 (11-40) 19 (7-35)  0.61  0.01 
Gender: Male 22 (58) 13 (54) 0.77 25 (71) 31 (82)  0.31  0.04 
Race: White 35 (92) 18 (75) 0.06 30 (86) 27 (71)  0.61  0.2 
Body mass index (kg/m
2
) 30 (23-37) 27 (19-37) 0.05 29 (20-38) 30 (20-38)  0.63  0.045 
        
0.13 
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Ischemic/ hepatectomy times         
CIT (hours) 6.5 (4.3-10.4) 6.4 (4-12) 0.86 4.6 (3.1-9.2) 4.5 (3.6-5.8)  0.07  <0.001 
Total donor WIT (minutes) 23 (14-39) 34 (19-83) 0.01 23 (15-33) 24 (18-43)  0.86   0.01 
Functional donor WIT (minutes) 15 (7-30) 32 (14-78) 0.001 18 (10-28) 20 (12-40)  0.52   0.01 
Recipient WIT (minutes) 21 (18-38) 27 (21-38) 0.001 19 (13-28) 20 (16-31)  0.06  <0.001 
Total WIT (donor functional 
WIT + recipient WIT) (minutes) 
37 (26-63) 58 (38-108) 0.001 37 (25-50) 39 (28-72)  0.07                 <0.001 
Hepatectomy time (minutes) 73(48-146) 84 (72-122) 0.26 73 (42-120) 66 (37-101) 0.94   0.01 
        
Legend: Data are presented as the median (range) or frequency (%) values. MELD: model for end-stage liver disease, AST: aspartate aminotransferase, ALT: 
alanine aminotransferase, HTK: Histidine-Tryptophan-Ketoglutarate, UW: University of Wisconsin, ECD: extended criteria donor, SCD: standard criteria 
donor, DCD: donation after cardiac death, CIT: cold ischemia time, WIT: warm ischemia time. 
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Table 2. Clinical outcomes of ECD DCD LTs stratified by eras and compared with propensity score matched DBD LTs 
 Era I 
ECD DCD n=24 
Era II 
ECD DCD 
n=38 
p-value 
 
Matched 
DBD 
n=124 
p-value 
(Era II ECD DCD vs. 
Matched DBD) 
Recipient laboratory values 
   
  
Peak ALT (U/L) 1274 (191-9635) 1236 (98-5740) 0.81 497 (46-4725) <0.001 
Peak AST (U/L) 1614 (117-12618) 2544 (271-13300) 0.12 685 (43-6684) <0.001 
PTD 7 Total Bilirubin (mg/dL) 4.1 (0.8-16.1) 2.6 (0.9-27.6) 0.08 2.9 (0.6-23.2) 0.56 
PTD 14 Total Bilirubin (mg/dL) 3.6 (0.9-14.1) 1.4 (0.5-47) 0.01 1.8 (0.4-21.7) 0.15 
PTD 30 Total Bilirubin (mg/dL) 1.6 (0.3-22.7) 0.8 (0.4-56) 0.03 1 (0.2-16.2) 0.15 
Early allograft dysfunction* 14 (58) 24 (63) 0.7 43 (35) <0.01 
 
Anastomotic biliary stricture 13 (54) 
 
8 (21) 
 
0.01 
 
37 (30) 
 
0.05 
Ischemic Cholangiopathy 4 (17) 2 (5) 0.01 3 (2) 0.42 
Hepatic artery thrombosis 1 (4) 1 (3) 0.9 1 (1) 0.61 
Re-transplantation within 1 year 2 (8) 1 (3) 0.8 2 (2) 0.82 
Length of hospital stay (days) 16 (0-80) 15 (7-31) 0.85 12 (0-66) 0.53 
30-day graft loss 2 (8) 0 0.07 10 (8) 0.06 
1-year graft loss 6 (25) 
 
2/32 (7)
†
 0.07 15 (12) 0.16 
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1-year patient death  4 (17) 1/32 (3)
†
 0.09 12 (10) 0.25 
      
Legend: Data are presented as the median (range) or frequency (%) values. AST: aspartate aminotransferase, ALT: alanine aminotransferase, PTD: post-
transplant day, ECD: extended criteria donor, DCD: donation after circulatory death, DBD: donation after brain death 
* Early allograft dysfunction defined as AST or ALT greater than 2000u/L in first 7 days, day 7 total bilirubin >=10.0 mg/dL, or day 7 INR >= 1.6. 
†
Note: for 1-year graft loss, patients with at least 12 months follow up were considered 
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Table 3: Extended criteria DCD livers and graft loss in Era I and II 
  
 
ECD variable/s 
Era I (n=24) Era II (n=38) 
Transplants Graft loss (%) Transplants Graft loss 
(%) 
Age >50 8 6 (75) 23 2 (9) 
BMI >35  4 1 (25) 7 0 
fWIT >30  8 4 (50) 6 0 
Macrosteatosis >30% 0 0 6 1 (17) 
Age >50 + BMI >35 3 3 (100) 1 0 
Age >50 + fWIT >30 0 0 1 0 
Age >50 + Macrosteatosis >30% 0 0 2 0 
BMI >35 + fWIT >30 1 0 1 0 
BMI >35 + Macrosteatosis >30% 0 0 0 0 
fWIT >30 + Macrosteatosis >30% 0 0 1 0 
 
 
Legend: Data are presented as the frequency of transplants and graft loss (%). ECD: extended criteria donor, fWIT: functional donor warm ischemia time, 
age in years, BMI in kg/m
2
, fWIT in minutes 
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